| 35.87 8.02 (28.8%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.07 |
1-year : | 49.13 |
| Resists | First : | 36.02 |
Second : | 42.07 |
| Pivot price | 23.89 |
|||
| Supports | First : | 24.12 |
Second : | 16.77 |
| MAs | MA(5) : | 27.7 |
MA(20) : | 23.66 |
| MA(100) : | 20.29 |
MA(250) : | 20.3 |
|
| MACD | MACD : | 2.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 94.7 |
D(3) : | 92.5 |
| RSI | RSI(14): 83.1 |
|||
| 52-week | High : | 36.02 | Low : | 13.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TECX ] has closed above the upper band by 28.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 249.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 36.02 - 36.15 | 36.15 - 36.26 |
| Low: | 27.1 - 27.22 | 27.22 - 27.34 |
| Close: | 35.61 - 35.84 | 35.84 - 36.05 |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Fri, 06 Mar 2026
Unveiling Bumps: How Tectonic Therapeutic’s Recent Moves Affect the Market - timothysykes.com
Thu, 05 Mar 2026
Tectonic Therapeutic (NASDAQ:TECX) Hits New 12-Month High - Here's Why - MarketBeat
Wed, 04 Mar 2026
Tectonic Therapeutic (NASDAQ:TECX) Trading Up 11.4% - What's Next? - MarketBeat
Mon, 02 Mar 2026
Tectonic Therapeutic to Participate in March Investor Conferences - The Manila Times
Sun, 01 Mar 2026
Tectonic Therapeutic to Participate in March Investor Conferences - Bitget
Fri, 27 Feb 2026
Tectonic Therapeutic, Inc. (TECX) Stock Analysis: A Promising Biotech with a Potential 227% Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 38.4 (%) |
| Held by Institutions | 74.3 (%) |
| Shares Short | 3,770 (K) |
| Shares Short P.Month | 3,740 (K) |
| EPS | -2.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.5 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -62 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -13.34 |
| PEG Ratio | 0 |
| Price to Book value | 2.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|